Showing results (161-170 of 194) with videos related to

Sort By:
Pageof 20
Open Forum Infectious Diseases|July 28, 2022
Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden SettingsAmita Gupta, Xin Sun, Sonya Krishnan, et al.
AIDS (London, England)|December 11, 2020
Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen statusSarah L Pett, Moira Spyer, Lewis J Haddow, et al.
Nature Communications|June 20, 2026
NK cell dysregulation may potentiate cardiovascular disease in adolescents with perinatally acquired HIV on antiretroviral therapyMario Alles, Manuja Gunasena, Aaren Kettelhut, et al.
The Journal of Infectious Diseases|November 19, 2014
HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation LevelsMichael A Eller, Marc S Opollo, Michelle Liu, et al.
The New England Journal of Medicine|July 21, 2017
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in AfricaJames Hakim, Victor Musiime, Alex J Szubert, et al.
Current HIV Research|October 6, 2025
Africa is an Essential Partner in the Research and Development of an HIV VaccineGlenda Gray, Carolyn Williamson, Linda-Gail Bekker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 14, 2019
Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid TissuesMeghan Rothenberger, Krystelle Nganou-Makamdop, Cissy Kityo, et al.
Open Forum Infectious Diseases|July 9, 2025
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 SitesCissy Kityo, Caitlyn McCarthy, Serena P Koenig, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2022
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trialSunil S Solomon, Sandra Wagner-Cardoso, Laura Smeaton, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Pageof 20